Mark Fishman

Mark C.
Fishman currently works at Beam Therapeutics, Inc., as Lead Independent Director from 2018, Aditum Bio Fund 1 LP, as Director, Versanis Bio, Inc., as Non-Executive Director, Teres Bio, Inc., as Director, Anteris Bio, Inc., as Director, The General Hospital Corp., as Chief-Pathways Clinical Service, and The Children's Hospital of Philadelphia, as Trustee-Emeritus.
Dr. Fishman also formerly worked at Novartis Institute for Functional Genomics, Inc., as Chairman, Semma Therapeutics, Inc., as Chairman from 2016 to 2019, Novartis International Pharmaceutical Ltd., as Director, Cardiovascular Research Center, as Founding Director, Geneception, Inc., as Director, Novartis AG, as Member-Executive Board, Novartis Institutes for Biomedical Research, Inc., as Founding President from 2002 to 2016, The Marine Biological Laboratory, as Trustee, and Harvard Medical School, as Professor.
Dr. Fishman received his undergraduate degree in 1972 from Yale University and doctorate degree in 1976 from Harvard Medical School.